Digital Content 
NEWS #PharmaBuzz
28 Feb 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/minerva-again-tangled-web-rejection-after-fda-nixes-schizophrenia-drug-2nd-time
10 May 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/05/10/2665474/32445/en/Minerva-Neurosciences-Announces-Update-on-its-New-Drug-Application-NDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
01 May 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/05/01/2658173/32445/en/Minerva-Neurosciences-Announces-the-NDA-Filing-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
17 Oct 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/10/17/2535492/32445/en/Minerva-Neurosciences-Receives-Refusal-to-File-Letter-from-FDA-for-its-New-Drug-Application-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Schizophrenia.html
22 Aug 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/08/22/2502130/32445/en/Minerva-Neurosciences-Submits-New-Drug-Application-to-FDA-for-Roluperidone-for-the-Treatment-of-Negative-Symptoms-in-Patients-with-Schizophrenia.html
03 Nov 2021
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2021/11/03/2326391/32445/en/Minerva-Neurosciences-Announces-FDA-Recommendation-for-Type-C-Meeting-to-Discuss-Evidence-for-Use-of-Roluperidone-as-Monotherapy-for-the-Treatment-of-Negative-Symptoms-in-Patients-.html
LOOKING FOR A SUPPLIER?
Share